Page 17 - Project Bioshield News Today

HyBryte™ Expanded Efficacy and Safety Data Presented at the American Academy of Dermatology Meeting News provided by Share this article Share this article PRINCETON, N.J., April 26, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman C...

Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCL News provided by Share this article Share this article PRINCETON, N.J., April 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has conditionally acc...

Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter News provided by Share this article Share this article PRINCETON, N.J., Feb. 24, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J...

Soligenix to Present at the 2021 BIO CEO & Investor Digital Conference News provided by Share this article Share this article PRINCETON, N.J., Feb. 11, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corpora...

  PRINCETON, N.J., Feb. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Hong Kong Registrar of Patents has granted a patent for the application titled "Formulations and Methods of Treatment of Skin Conditions" (No. 16102842.8), published on January 29, 2021 under Publication No. 1214771...

Millions earmarked for vaccine research was misappropriated, watchdog says By Audrey McNamara January 28, 2021 / 3:35 PM / CBS News Millions of dollars intended for vaccine research and public health emergencies were for years misused by the Department of Health and Human Services, according to a new report from independent watchdog group U.S. Office of Special Counsel. An anonymous whistleblower sparked an investigation into HHS Office of the Assistant Secretary for Pre...

Share this article Share this article PRINCETON, N.J., Jan. 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has signed an exclusive Supply, Distribution and Services Agreement with Daavlin.  Securing long-term supply and distribution of a commercially ready light device is an integral ...

A transcript of the presentation will be archived for 30 days following the event. About Oral Mucositis Mucositis is the clinical term for damage done to the mucosa by anticancer therapies. It can occur in any mucosal region, but is most commonly associated with the mouth, followed by the small intestine. It is estimated, based upon review of historic published studies and reports and an interpolation of data on the incidence of mucositis, that mucositis affects approximately 500,000 people in ...

Winter. not surprisinglsurprisingly, wew unprepared we really were back then. how much have we improved since then? >> well, so for dark winter, specifically, they were simulating the effects of a smallbox attack, and smallpox is a very interesting case, in part because the virus itself is extremely limited in its accessibility. and so the only way terrorist cells would be able to get smallpox is either by synthesizing, which is extremely difficult to do, or by getting loose smallpox in the same...

No-bid contract with firms to ties to democrat. tonight in fox include exclusive, correspondent james rosen has a similar account on what could be life and death in post-9/11 era. >> from the terror of the anthrax attacks born an initiative president bush called project bioshield. >> the budget will have $6 million to make available effective vaccine and treatment. >> since then, handful of biodefense firms using lobbyists and the competitive bidding conferentract had huge awards. the department...